Lipoproteins, LDL - Pharmacology
Research News and Information

Sunday, November 22, 2009

Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.

29 Nov 2009 The role of OxLDL in the generation and progression of atherosclerosis is well admitted. In addition, it is well known that atherosclerosis is often accompanied by perturbations in bone remodeling, resulting in osteoporosis. In the current studies, ... Read more...

Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factor-kappaB activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein.

29 Jun 2009 Atherosclerosis is a complex inflammatory arterial disease. Oxidized low-density lipoprotein (ox-LDL) is directly associated with chronic vascular inflammation. In the current study, we tested the hypothesis that ginkgolide B, a component of ... Read more...

Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon.

28 Jun 2009 Lipid-laden foam macrophages are emerging as key players in early atherogenesis. Even though cytoplasmic lipid bodies (lipid droplets) are now recognized as organelles with cell functions beyond lipid storage, the mechanisms controlling lipid body ... Read more...

Latest indexed articles for 'Lipoproteins, LDL - Pharmacology'

These are the very latest articles for this heading:

• Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. 29 Nov 2009
• Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factor-kappaB activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein. 29 Jun 2009
• Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon. 28 Jun 2009
• Coatings of low-density lipoprotein and synthetic glycoconjugates as substrata for hepatocytes. 30 May 2009
• A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro. 25 May 2009
• Vaccination against atherosclerosis? Induction of atheroprotective immunity. 24 May 2009
• Chicken scavenger receptors and their ligand-induced cellular immune responses. 12 May 2009
• [The effect of LDL on the activity of proinflammatory secretory phospholipase A2 (IIA) depends on the degree of their oxidation] 29 Apr 2009
• Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. 26 Apr 2009
• MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. 15 Apr 2009
• High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. 4 Apr 2009
• Modification of platelet shape change parameter by oxidized lipoprotein from beta-thalassemia/Hemoglobin E. 30 Mar 2009
• Inhibitory effects of grape seed procyanidins on foam cell formation in vitro. 23 Mar 2009
• Protective effects of a benzoxazine derivative against oxidized LDL-induced apoptosis and the increases of integrin beta4, ROS, NF-kappaB and P53 in human umbilical vein endothelial cells. 19 Mar 2009
• Effect of glutamine on post-thaw motility of bull spermatozoa after association with LDL (low density lipoproteins) extender: preliminary results. 15 Mar 2009
• A novel gene silencer, pyrrole-imidazole polyamide targeting human lectin-like oxidized low-density lipoprotein receptor-1 gene improves endothelial cell function. 27 Feb 2009
• Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. 27 Feb 2009
• Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. 17 Feb 2009
• Effect of oxidized low-density lipoprotein on survival and function of endothelial progenitor cell mediated by p38 signal pathway. 30 Jan 2009
• Modification of platelet shape change parameter by modified phospholipids in oxidized LDL. 30 Jan 2009

See a longer list of these articles.

Technical information about 'Lipoproteins, LDL'

Definition: A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.

Registry Number: 0

Descriptor UI: D008077

Alternative terms: Lipoproteins, LDL; LDL Lipoproteins; Low-Density Lipoproteins; Lipoproteins, Low-Density; Low Density Lipoproteins; beta-Lipoproteins; beta Lipoproteins; LDL-1; LDL1; Low-Density Lipoprotein 1; Low Density Lipoprotein 1; LDL(1); LDL-2; LDL2; Low-Density Lipoprotein 2; Low Density Lipoprotein 2; LDL(2);

Related Mesh Headings: Receptors, LDL;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D10.532.515; D12.776.521.550;

History Note: 74(72)

Technical Notes: /defic: consider also HYPOBETALIPOPROTEINEMIAS